Autologous Costal Osteochondral Transplantation for Talar Osteochondral Lesions

NCT ID: NCT05942430

Last Updated: 2023-09-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-09-01

Study Completion Date

2028-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to evaluate the effectiveness and safety of autologous costal osteochondral transplantation in the treatment of Hepple Stage V talar osteochondral lesions, compared with autologous osteoperiosteal transplantation. The main question it aims to answer is:

• Whether autologous costal osteochondral transplantation can achieve better clinical outcomes and cartilage repair quality with lower donor site morbidity than autologous osteoperiosteal transplantation in the treatment of Hepple Stage V talar osteochondral lesions.

Participants will be randomly assigned to the intervention group (undergoing autologous costal osteochondral transplantation) or the control group (undergoing autologous osteoperiosteal transplantation). Both groups of participants will receive the same postoperative rehabilitation process and follow-up evaluation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Articular Cartilage Defect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The costa group

Autologous costal osteochondral transplantation

Group Type EXPERIMENTAL

Autologous costal osteochondral transplantation

Intervention Type PROCEDURE

Operating steps:

1. Arthroscopic examination of the size and location of the talar osteochondral lesion;
2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;
3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;
4. Trim the autograft according to the size of the lesion;
5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;
6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

The ilium group

Autologous iliac osteoperiosteal transplantation

Group Type ACTIVE_COMPARATOR

Autologous iliac osteoperiosteal transplantation

Intervention Type PROCEDURE

Operating steps:

1. Arthroscopic examination of the size and location of the talar osteochondral lesion;
2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.
3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;
4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;
5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Autologous costal osteochondral transplantation

Operating steps:

1. Arthroscopic examination of the size and location of the talar osteochondral lesion;
2. Make a transverse incision (approximately 4 cm long) at the osteochondral junction of the fifth or sixth rib, and harvest an osteochondral column from the rib;
3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;
4. Trim the autograft according to the size of the lesion;
5. Fill the peri-lesion cavity with cancellous bone, and finally embed the costal osteochondral autograft into the talar defect, ensuring that the cartilage surface of the transplant to be flush with the normal talar cartilage around it;
6. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

Intervention Type PROCEDURE

Autologous iliac osteoperiosteal transplantation

Operating steps:

1. Arthroscopic examination of the size and location of the talar osteochondral lesion;
2. Make an incision along the anterior iliac crest. At the time of exposure, pay attention not to damage the periosteum. Obtain a cylindrical osteoperiosteal column by an appropriate-sized harvester tube.
3. Thoroughly remove the talar osteochonral lesion through arthrotomy or Chevron osteotomy of the medial malleolus;
4. Fill the peri-lesion cavity with cancellous bone, and finally embed the iliac osteoperiosteal autograft into the talar defect, ensuring that the periosteum surface of the transplant to be flush with the normal talar cartilage around it;
5. Suture the joint capsule or reduct and fix the medial malleolus, and close the incision layer by layer.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Symptomatic Hepple stage V talar osteochondral lesions with a lesion depth ≥5 mm and an AOFAS score ≤80 points;
* Failed conservative treatment for at least 6 months;
* Unilateral talar osteochondral lesions without corresponding lesions on the tibial side;
* Willingness to participate in this clinical trial and signing an informed consent form.

Exclusion Criteria

* Combined with lower limb deformity.
* Combined with hip or knee joint diseases.
* Combined with ipsilateral ankle arthritis with joint space narrowing .
* Diagnosis of gouty arthritis of the ankle joint.
* Combined with osteoporosis (T score \<-2.5).
* Other conditions considered inappropriate for participation in this clinical trial by the researchers.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Third Affiliated Hospital of Southern Medical University

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Canjun Zeng

Director of the Department of Foot and Ankle Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Canjun Zeng, PhD

Role: PRINCIPAL_INVESTIGATOR

The Third Affiliated Hospital of Southern Medical University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Third Affiliated Hospital of Southern Medical University

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hao Guo, MD

Role: CONTACT

+8617612003968

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Junyan Li

Role: primary

00-86-20-62784067

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

YL202203

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

2023-Lunshen-017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Study of Meniscal Allografts
NCT01059409 TERMINATED NA